JP2011525531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525531A5 JP2011525531A5 JP2011516297A JP2011516297A JP2011525531A5 JP 2011525531 A5 JP2011525531 A5 JP 2011525531A5 JP 2011516297 A JP2011516297 A JP 2011516297A JP 2011516297 A JP2011516297 A JP 2011516297A JP 2011525531 A5 JP2011525531 A5 JP 2011525531A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- brain lesions
- human subject
- once
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 206010051290 Central nervous system lesion Diseases 0.000 claims 13
- 201000006417 multiple sclerosis Diseases 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 229910052688 Gadolinium Inorganic materials 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000008215 water for injection Substances 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000005549 deoxyribonucleoside Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- -1 phosphorothioate diester Chemical class 0.000 claims 1
- 208000024335 physical disease Diseases 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical class [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13297308P | 2008-06-23 | 2008-06-23 | |
| US61/132,973 | 2008-06-23 | ||
| PCT/US2009/003760 WO2010008474A2 (en) | 2008-06-23 | 2009-06-23 | Methods for treating multiple sclerosis using antisense oligonucleotides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208153A Division JP6131230B2 (ja) | 2008-06-23 | 2014-10-09 | アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525531A JP2011525531A (ja) | 2011-09-22 |
| JP2011525531A5 true JP2011525531A5 (enExample) | 2012-08-09 |
| JP5988581B2 JP5988581B2 (ja) | 2016-09-07 |
Family
ID=41550900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516297A Expired - Fee Related JP5988581B2 (ja) | 2008-06-23 | 2009-06-23 | アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法 |
| JP2014208153A Expired - Fee Related JP6131230B2 (ja) | 2008-06-23 | 2014-10-09 | アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208153A Expired - Fee Related JP6131230B2 (ja) | 2008-06-23 | 2014-10-09 | アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8415314B2 (enExample) |
| EP (2) | EP2318424B1 (enExample) |
| JP (2) | JP5988581B2 (enExample) |
| AU (1) | AU2009271678B2 (enExample) |
| CA (1) | CA2728562C (enExample) |
| DK (2) | DK2937358T3 (enExample) |
| ES (2) | ES2532404T3 (enExample) |
| WO (1) | WO2010008474A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532404T3 (es) | 2008-06-23 | 2015-03-26 | Antisense Therapeutics Ltd | Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido |
| AU2011301712C1 (en) * | 2010-09-17 | 2017-01-05 | Antisense Therapeutics Ltd | Method for reducing the number of certain circulating leukocytes in a human subject |
| EP3294889B1 (en) * | 2015-05-11 | 2021-01-06 | Murdoch University | Multiple sclerosis treatment |
| AU2018286483C1 (en) * | 2017-06-16 | 2024-10-31 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| KR20210018820A (ko) * | 2018-05-04 | 2021-02-18 | 안티센스 테라퓨틱스 엘티디 | 치료 용도 및 방법 |
| WO2020223762A1 (en) * | 2019-05-06 | 2020-11-12 | Antisense Therapeutics Ltd | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242591B1 (en) * | 1997-10-15 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Synthesis of sulfurized 2'-substituted oligonucleotides |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
| JP2008516991A (ja) * | 2004-10-20 | 2008-05-22 | アンチセンス セラピューティクス リミテッド | インテグリンα４発現のアンチセンス調節 |
| ES2532404T3 (es) | 2008-06-23 | 2015-03-26 | Antisense Therapeutics Ltd | Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido |
-
2009
- 2009-06-23 ES ES09798248.2T patent/ES2532404T3/es active Active
- 2009-06-23 EP EP09798248.2A patent/EP2318424B1/en not_active Not-in-force
- 2009-06-23 DK DK15155831.9T patent/DK2937358T3/da active
- 2009-06-23 WO PCT/US2009/003760 patent/WO2010008474A2/en not_active Ceased
- 2009-06-23 AU AU2009271678A patent/AU2009271678B2/en not_active Ceased
- 2009-06-23 ES ES15155831T patent/ES2699891T3/es active Active
- 2009-06-23 US US12/456,883 patent/US8415314B2/en not_active Expired - Fee Related
- 2009-06-23 EP EP15155831.9A patent/EP2937358B1/en active Active
- 2009-06-23 JP JP2011516297A patent/JP5988581B2/ja not_active Expired - Fee Related
- 2009-06-23 CA CA2728562A patent/CA2728562C/en active Active
- 2009-06-23 DK DK09798248T patent/DK2318424T3/en active
-
2013
- 2013-03-22 US US13/848,811 patent/US8759314B2/en active Active
-
2014
- 2014-10-09 JP JP2014208153A patent/JP6131230B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009154777A4 (en) | Process for preparing and drying solid rasagiline base | |
| US10538768B2 (en) | Modified TGF-beta oligonucleotides | |
| JP2012530715A5 (enExample) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| EP2785349B1 (en) | Combination treatment of cancer | |
| JP2011525531A5 (enExample) | ||
| US9161946B2 (en) | Dosing methods for treating disease | |
| JP2018520685A (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2018512127A5 (enExample) | ||
| JP2012144512A (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
| JP2016513110A5 (enExample) | ||
| JP5674923B2 (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| JP2024037841A5 (enExample) | ||
| JPWO2020061177A5 (enExample) | ||
| KR20140025461A (ko) | 진행성 고형 종양의 치료 방법 | |
| CA3227115A1 (en) | Unc13a antisense oligonucleotides | |
| AU2016287580A2 (en) | Compositions and methods for the treatment of viral infection | |
| JP2014513144A (ja) | 進行性又は転移性固形悪性腫瘍を含む固形悪性腫瘍の治療方法 | |
| US20160151406A1 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| US20240229028A1 (en) | Splice-switching oligonucleotides and methods of use | |
| WO2010008474A4 (en) | Methods for treating multiple sclerosis using antisense oligonucleotides | |
| US20170314025A1 (en) | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease | |
| AU2005327506B2 (en) | Antisense modulation of integrin alpha4 expression | |
| JP2011505798A5 (enExample) | ||
| US20230113556A1 (en) | Antisense nucleic acid targeting apoc3 |